Phoenix Molecular Designs

We are honored that our SABCS poster, # P4-08-27: PMD-026, a First-in-Class RSK Inhibitor, Overcomes Acquired Resistance to CDK4/6 Inhibitors or Aromatase Inhibitors in HR+/HER2- Breast Cancer Preclinical Models, has won the 2024 GRASP Advocate Choice Award. This recognition underscores the importance of collaboration between patients, clinicians, and researchers in advancing meaningful solutions for breast cancer. Thank you to GRASP for this incredible recognition! Join us on Tuesday, December 17, from 2:00–3:30 PM ET, during the GRASP Poster Walkthroughs, where our work will be highlighted. #GRASP #BreastCancerResearch #PhoenixMD #PMD026

We’re thrilled to share a monumental step forward in cancer research, as featured in the Blood Cancer Journal! Our very own PMD-026, a first-in-class RSK inhibitor, is a promising and unconventional approach to treating FLT3-ITD acute myeloid leukemia (AML)—a notoriously challenging cancer to treat. - Of fundamental significance, RSK1 ranked as the top gene that controls AML growth. The study, conducted in collaboration with leading scientists including Stephen Oh, highlights PMD-026's potential to: - Induce apoptosis in FLT3-ITD AML cells. - Triggers a protein degradation pathway. - Provide a novel therapeutic strategy for treatment-resistant AML patients. What makes this achievement truly special is the profound impact PMD-026 has as a single agent, offering hope for patients battling aggressive forms of AML. This work exemplifies our mission to innovate and push the boundaries of what's possible in oncology. We are excited to continue driving this momentum forward! Read the full study in the Blood Cancer Journal: https://lnkd.in/gYfa4gbA #CancerResearch #Oncology #AML #BiotechInnovation #PMD026

Breast cancer survival is improved through Medicaid Expansion: Bridging the Care Gap A powerful new study shows how Medicaid expansion under the Affordable Care Act has improved care access and outcomes for women with hormone receptor (HR)-negative, HER2-positive breast cancer—an aggressive type that demands timely intervention. In states that adopted Medicaid expansion, patients saw improvements by: 3.81% increase in 2-year survival among patients with stage III disease 2.43% boost in beginning treatment within 60 days post-diagnosis. 1.17% increase in two-year survival rates. 0.58% increase in receiving treatment aligned with clinical guidelines. These gains highlight the critical role of accessible healthcare in improving survival and equity in breast cancer care. At PhoenixMD, we’re proud to advance innovations that support early, effective intervention for all patients facing breast cancer. https://lnkd.in/gTMM2sh2 #BreastCancerAwareness #HealthcareEquity #PhoenixMD #MedicaidExpansion #AffordableCareAct #BreastCancerAwarenessMonth

Looking forward to the Biotechnology Innovation Organization Investor Forum at the Fairmont in San Francisco on October 15-16, 2024! PhoenixMD’s Founder and CEO, Sandra Dunn, will be there to connect with investors and industry leaders. With our focus on developing groundbreaking therapies for breast cancer, it’s the perfect opportunity to discuss collaborations and partnerships.   When: October 15-16, 2024 Where: Fairmont, San Francisco Reach out to schedule a meeting! #BioInvestorForum #Biotech #BreastCancer #Innovation

With over 2.3 million new breast cancer cases expected this year and 310,000 in the U.S. alone, progress in treatment is more critical than ever. Thanks to advances in research, breast cancer mortality has decreased by an estimated 44%.  These achievements show how far we’ve come, but they also remind us of the work still ahead. New approaches, such as CDK4/6 inhibitors like Kisqali, have revolutionized treatment for HR+/HER2- breast cancer, offering more precise and targeted options for patients. The recent FDA approval of Kisqali for early-stage breast cancer is a significant milestone, showing how innovations in targeted therapies can bring hope and improved outcomes. However, many patients—particularly those with early-stage or high-risk disease—still face limited therapeutic choices. As research continues, the future of breast cancer treatment lies in developing more precise, molecularly targeted therapies that not only extend survival but also minimize side effects, improving patients' quality of life. As we’ve seen with recent breakthroughs, the promise of innovation is real, and we are committed to advancing treatments that one day may also make a difference for all breast cancer patients. This month, we reflect on the progress made and renew our focus on driving forward the next generation of treatments. #BreastCancerAwareness #BreastCancerResearch #WomensHealth #TargetedTherapies #InnovatingForPatients #BreastCancerAwarenessMonth

Breast Cancer Awareness Month has officially begun, and at Phoenix Molecular Designs, we are committed to advancing the fight against this disease. Throughout October, we will share insights, research progress, and stories from the incredible individuals leading the charge.   Did you know that 1 in 8 women will develop breast cancer in their lifetime? Raising awareness is the first step in reducing those numbers. Join us in spreading the word and supporting life-saving research. Together, we can make a difference. #BreastCancerAwareness #PhoenixMD #ResearchForACure

We are pleased to announce the appointment of Stephen Oh to the Phoenix Molecular Designs Advisory Board. Dr. Oh is globally recognized for his groundbreaking research in identifying RSK as a novel target for treating myeloproliferative neoplasms (MPNs) such as myelofibrosis and acute myeloid leukemia (AML). His work, published in Nature Cancer 2023, has brought international acclaim and new possibilities for therapeutic development. His expertise will significantly contribute to our efforts in pioneering first-in-class RSK kinase inhibitors, like PMD-026, designed to offer life-changing treatments for cancer patients globally. We’re excited to work alongside Dr. Oh and drive advancements in cancer therapeutics that minimize side effects and improve patient outcomes. Please join us in welcoming Dr. Oh to the PhoenixMD team! Read more: https://shorturl.at/fxkpt #PhoenixMD #CancerResearch #LifeSciences #RSKInhibitors #AdvisoryBoard #Oncology

Our Commercialization and Patient Access expert, Mackenzie Sharp, MPH, recently attended the San Francisco Women's Health PAC event. We're proud to support leaders in healthcare who are committed to driving meaningful change and improving patient outcomes! #WomensHealth #HealthcareLeadership #PatientAccess #Innovation

We support the bipartisan Find It Early Act, which would ensure full coverage of these essential screenings, helping to save lives through early detection. Every woman deserves access to the best possible care, and this legislation is a crucial step toward making that a reality.

We’re thrilled to announce Fred Eshelman, Pharm.D., has joined our Board of Directors! With his impressive background in pharmaceuticals and healthcare, Fred is a perfect fit for PhoenixMD as we advance our Phase 2 trial of PMD-026 for metastatic HR+ breast cancer.   Fred’s experience in transforming companies will be valuable as we continue our work in cancer treatment. Welcome, Fred!   #CancerResearch #OncologyInnovation #PharmaLeadership #PhoenixMD   https://shorturl.at/AG0It